Research Topics
Species | Suhendan EkmekciogluSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24Eva G Caudell
Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Immunol 168:6041-6. 2002....
Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cellsSuhendan Ekmekcioglu
Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Nutr Cancer 63:940-9. 2011..Based on the responsible molecular mechanisms of Zyflamend, our study highlights the importance of the use of herbal preparations for the prevention and treatment of cancer...
Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24Suhendan Ekmekcioglu
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 362, Houston, TX 77030, USA
Cytokine 43:34-44. 2008..In summary, we described a novel pathway of MDA7/IL-24 regulation of apoptosis in melanoma tumors via endogenous IFN-beta induction followed by IRF regulation and TRAIL/FasL system activation...
Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanismSunil Chada
Introgen Therapeutics, Inc, Houston, TX 77030, USA
Mol Ther 10:1085-95. 2004..This study defines a tumor-selective cytotoxic bystander role for secreted MDA-7 protein and identifies a novel receptor-mediated, STAT3-independent, and PKR-independent death pathway...
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cellsMingzhong Zheng
Introgen Therapeutics, 2250 Holcombe Boulevard, Houston, TX 77030, USA
Mol Cancer Ther 7:3842-51. 2008..This study shows that IL-24 can play a significant role in overcoming temozolomide resistance and that the clinical efficacy of temozolomide may be improved by using a biochemotherapy combination with IL-24...
Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cellsSuhendan Ekmekcioglu
Department of Bioimmunotherapy, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Mol Cancer Ther 2:9-17. 2003..These studies demonstrate that expression of the MDA-7 tumor suppressor can negatively regulate iNOS expression in malignant melanoma cell lines...
Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10Mingzhong Zheng
Introgen Therapeutics Inc, 2250 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Immunol Immunother 56:205-15. 2007....
Association of activated c-Met with NRAS-mutated human melanomasChandrani Chattopadhyay
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Cancer 131:E56-65. 2012..On the basis of these experimental results, we propose that c-Met inhibition may be a useful therapeutic strategy for melanomas with NRAS mutations, as well as some tumors with a wt/wt genotype...
Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanomaYong Qin
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Res 9:1537-50. 2011..These results indicate that the endogenous IL-1 system is functional in most human melanoma and interrupting its signaling inhibits the growth of IL-1-positive melanoma cells...
Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosisElizabeth A Grimm
Department of Experimental Therapeutics, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Nitric Oxide 19:133-7. 2008..Our goal is to understand the aberrant biology leading to this curious phenomenon, and to regulate it in favor of patient treatments...
Tumor iNOS predicts poor survival for stage III melanoma patientsSuhendan Ekmekcioglu
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Cancer 119:861-6. 2006..The ability of iNOS to predict outcomes for these patients may be independent of other known prognostic factors, providing a new molecular marker with significant potential for clinical utility...
Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytesJohn B Mumm
Department of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Interferon Cytokine Res 26:877-86. 2006..Thus, we demonstrated that the secreted, glycosylated, dimeric, human IL-24 is immunomodulatory to monocytes and exhibits tumor cell growth inhibition...
Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cellsMingzhong Zheng
Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Melanoma Res 14:165-71. 2004..Therefore, curcumin should be considered further as a potential therapy for patients with melanoma...
MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 familySunil Chada
Introgen Therapeutics, Inc, 2250 Holcombe Blvd, Houston, TX 77030, USA
Int Immunopharmacol 4:649-67. 2004..Thus, mda-7 is a unique multifunctional cytokine in the IL-10 family and may have potent antitumor utility in a clinical setting...
Clinical correlates of NRAS and BRAF mutations in primary human melanomaJulie A Ellerhorst
Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 17:229-35. 2011..This study was designed to test the hypothesis that primary human cutaneous melanomas harboring mutations in NRAS or BRAF display a more aggressive clinical phenotype than tumors wild type at both loci...
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cellsAlexis L Stewart
Department of Research, Introgen Therapeutics, Inc, Houston, Texas 77030, USA
Mol Med 8:451-61. 2002..Thus, PI3K blockade via Ad-PTEN may be a promising approach for the treatment of early- and late-stage melanoma, even in tumors that do not harbor PTEN mutations...
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapyAndrew G Sikora
Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 16:1834-44. 2010..We tested the hypothesis that targeted iNOS inhibition would interfere with human melanoma growth and survival in vivo in a preclinical model...
NO news is not necessarily good news in cancerSuhendan Ekmekcioglu
Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Curr Cancer Drug Targets 5:103-15. 2005..This balance may serve as an important focal point in determining patient response to therapy. The ability to control this balance could significantly influence outcome...
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatmentHong Zhou
Department of Experimental Therapeutics, UT M D Anderson Cancer Center, Houston, TX, USA
J Invest Dermatol 133:1052-62. 2013..We conclude that Fn14 is a therapeutic target in melanoma and the hSGZ construct appears to warrant further development as a therapeutic agent against Fn14-positive melanoma...
The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10Keiji Tanese
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Int J Cancer 131:891-901. 2012..Inhibiting NO induces an antitumorigenic environment, and thus, iNOS should be considered to be an important therapeutic target in melanoma...
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatmentCindy S Hwang
School of Medicine, Baylor College of Medicine, Houston, Texas, USA
Melanoma Res 18:241-5. 2008..A better understanding of the AKT and mitogen-activated protein kinase pathways is needed to optimize the clinical benefit of targeted therapy, such as imatinib...
Implications of tissue transglutaminase expression in malignant melanomaJansina Y Fok
Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Mol Cancer Ther 5:1493-503. 2006..Overall, our results suggest that TG2 expression contributes to the development of chemoresistance in malignant melanoma cells by exploiting integrin-mediated cell survival signaling pathways...
A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxideAnn-Marie Simeone
Department of Bioimmunotherapy, Sections of Immunobiology and Drug Carriers, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Mol Cancer Ther 1:1009-17. 2002..When combined with 4-HPR, IFN-gamma and TAM enhanced NOSII expression. Thus, we have identified a novel mechanism by which 4-HPR induces apoptosis in breast cancer cells, i.e., by increasing NOS expression to induce NO production...
Loss of MDA-7 expression with progression of melanomaJulie A Ellerhorst
Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
J Clin Oncol 20:1069-74. 2002..As a secondary objective, we analyzed MDA-7 protein expression in primary melanomas for correlation with predictors of outcome and with survival...
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanomaJahan S Khalili
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Clin Cancer Res 18:5329-40. 2012....
Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screeningYong Qin
Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Pigment Cell Melanoma Res 26:97-112. 2013....
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patientsAlex W Tong
Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
Mol Ther 11:160-72. 2005..Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating events that are consistent with the preclinical features of MDA-7/IL-24...
